Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Background: Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of liver cancer primarily affecting children and young adults. Although considered a subset of hepatocellular carcinoma (HCC), FLC has unique molecular and pathologic characteristics, suggesting that it may require different tre...

Full description

Bibliographic Details
Main Authors: Krista Y. Chen, Aleksandra Popovic, David Hsiehchen, Marina Baretti, Paige Griffith, Ranjan Bista, Azarakhsh Baghdadi, Ihab R. Kamel, Sanford M. Simon, Rachael D. Migler, Mark Yarchoan
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
fibrolamellar hepatocellular carcinoma
liver cancer
immune checkpoint inhibitor
anti-PD-1 therapy
Online Access:https://www.mdpi.com/2072-6694/14/21/5347

Internet

https://www.mdpi.com/2072-6694/14/21/5347

Similar Items